These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26473193)

  • 1. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
    Hingorani P; Missiaglia E; Shipley J; Anderson JR; Triche TJ; Delorenzi M; Gastier-Foster J; Wing M; Hawkins DS; Skapek SX
    Clin Cancer Res; 2015 Oct; 21(20):4733-9. PubMed ID: 26473193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
    Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification of rhabdomyosarcoma and its molecular basis.
    Parham DM; Barr FG
    Adv Anat Pathol; 2013 Nov; 20(6):387-97. PubMed ID: 24113309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
    Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
    Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
    Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
    Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
    Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
    Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
    Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
    Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
    Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
    La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
    Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
    Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
    Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
    Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
    J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.